Samik Pharm Co

Samik Pharm Co EBIT Margin

The EBIT Margin (Operating Margin) of Samik Pharm Co (014950.KQ) as of Oct 19, 2026 is 5.45 %. In the previous year, EBIT Margin (Operating Margin) was 5.46 % — a change of -0.10% (lower).

EBIT Margin

5.45 %

YoY

-0.10%

Last updated:

EBIT Margin (Operating Margin) of Samik Pharm Co is 2025 5.45 % . EBIT Margin (Operating Margin) of Samik Pharm Co was 2024 5.46 % . It decreases by -0.10% lower compared to the previous year.

For Samik Pharm Co, the operating (EBIT) margin of 5.5% is broadly stable versus 5.5% a few years ago.

The Samik Pharm Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2023
5.46 KRW
Jan 1, 2025
5.45 KRW
The Samik Pharm Co EBIT Margin history
YEAREBIT MarginYoY
5.45 %-0.10%
5.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Samik Pharm Co Stock analysis

What does Samik Pharm Co do? Samik Pharm Co Ltd is a company based in Incheon, South Korea, with an upcoming IPO scheduled for October 27, 2025. The company operates within the pharmaceutical industry, focusing on the manufacturing and sales of various pharmaceutical products. Its product portfolio includes medications for circulatory system treatments, such as Cesar Plus and Eravix tablets, diabetes management solutions like Griffin and Gluemser tablets, digestive system treatments including Samik Pharmotidine and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi and Seklfen tablets. The company also produces drugs for treating acute or recurrent vaginal candidiasis, motion sickness in children, and alopecia. Samik Pharm Co Ltd distributes its products both domestically within South Korea and internationally. The company's website is https://www.samik.co.kr/. It is listed under the ticker 014950.KQ with ISIN KR7014950000. The company is headquartered in Incheon, South Korea, and is engaged in the production and sale of pharmaceuticals. Samik Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Samik Pharm Co stock

EBIT Margin (Operating Margin) of Samik Pharm Co is 5.45 % in 2025.

EBIT Margin (Operating Margin) of Samik Pharm Co changed from 5.46 % to 5.45 %, representing a -0.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Samik Pharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Samik Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Samik Pharm Co

All Key Metrics — Samik Pharm Co